Emergent Biosolutions (EBS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Sales | 270,500 | 337,900 | 164,300 | 327,400 | 239,900 |
| Cost of Goods | 176,800 | 190,600 | 152,900 | 220,200 | 147,200 |
| Gross Profit | 93,700 | 147,300 | 11,400 | 107,200 | 92,700 |
| Operating Expenses | 336,600 | 440,800 | 159,900 | 166,500 | 138,200 |
| Operating Income | -242,100 | -292,900 | -147,600 | -59,100 | -45,300 |
| Interest Expense | 19,700 | 28,600 | 17,900 | 12,800 | 8,500 |
| Other Income | -4,100 | 71,300 | 4,900 | 6,700 | -13,400 |
| Pre-tax Income | -265,900 | -250,200 | -160,600 | -65,200 | -67,200 |
| Income Tax | -2,500 | 11,200 | 25,600 | -800 | 19,900 |
| Net Income Continuous | -263,400 | -261,400 | -186,200 | -64,400 | -87,100 |
| Net Income | $-263,400 | $-261,400 | $-186,200 | $-64,400 | $-87,100 |
| EPS Basic Total Ops | -5.08 | -5.16 | -3.71 | -1.27 | -1.75 |
| EPS Basic Continuous Ops | -5.08 | -5.16 | -3.71 | -1.28 | -1.75 |
| EPS Diluted Total Ops | -5.08 | -5.16 | -3.71 | -1.27 | -1.75 |
| EPS Diluted Continuous Ops | -5.08 | -5.16 | -3.71 | -1.28 | -1.75 |
| EBITDA(a) | $9,800 | $-251,100 | $-112,000 | $-15,700 | $-12,000 |